Evidence map›Paper›PMID 33540768›Full record

ArticleJournal of personalized medicine2021

Functional Assessment of 12 Rare Allelic

Masaki Kumondai, Akio Ito, Evelyn Marie Gutiérrez Rico, Eiji Hishinuma, Akiko Ueda, Sakae Saito, Tomoki Nakayoshi, Akifumi Oda, Shu Tadaka, Kengo Kinoshita and 4 more

Open access · goldAbstract read
In one paragraph

Article in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Identification andFrontiers in endocrinology · 2023
    Article
  3. Clinical significance of the series ofFrontiers in cardiovascular medicine · 2022
    Article
  4. Article
  5. Functional Characterization of 21 Rare AllelicJournal of personalized medicine · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Masaki KumondaiLaboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan.ORCID 0000-0002-2333-2847
Akio ItoLaboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan.
Evelyn Marie Gutiérrez RicoLaboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan.
Eiji HishinumaAdvanced Research Center for Innovations in Next-Generation Medicine, Tohoku University, Sendai 980-8575, Japan.
Akiko UedaAdvanced Research Center for Innovations in Next-Generation Medicine, Tohoku University, Sendai 980-8575, Japan.
Sakae SaitoTohoku Medical Megabank Organization, Tohoku University, Sendai 980-8575, Japan.
Tomoki NakayoshiFaculty of Pharmacy, Meijo University, Nagoya 468-8503, Japan.
Akifumi OdaFaculty of Pharmacy, Meijo University, Nagoya 468-8503, Japan.
Shu TadakaTohoku Medical Megabank Organization, Tohoku University, Sendai 980-8575, Japan.
Kengo KinoshitaTohoku Medical Megabank Organization, Tohoku University, Sendai 980-8575, Japan.ORCID 0000-0003-3453-2171
Masamitsu MaekawaDepartment of Pharmaceutical Sciences, Tohoku University Hospital, Sendai 980-8574, Japan.ORCID 0000-0001-6723-0298
Nariyasu ManoDepartment of Pharmaceutical Sciences, Tohoku University Hospital, Sendai 980-8574, Japan.
Noriyasu HirasawaLaboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan.
Masahiro HiratsukaLaboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan.
Tohoku University · JPMeijo University · JP

Funding

Japan Agency for Medical Research and Development 20kk0305009Japan Agency for Medical Research and Development JP20km0105001 and JP20km0105002Japan Society for the Promotion of Science 19J10744
6 · The paper itself

Abstract

Cytochrome P450 2C9 (CYP2C9) is an important drug-metabolizing enzyme that contributes to the metabolism of approximately 15% of clinically used drugs, including warfarin, which is known for its narrow therapeutic window. Interindividual differences in CYP2C9 enzymatic activity caused by

Indexed as

cytochrome P450 2C9drug metabolismgenetic variation(S)-warfarintolbutamide

Identifiers

PMID33540768
PMCPMC7912942
OpenAlexW3127985472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.